Search Results for "Oxycodone Hydrochloride 5 Mg Tablet"
Original Source: OXYCODONE HYDROCHLORIDE [Mallinckrodt, Inc.]
OXYCODONE HYDROCHLORIDETablets USP CII 5 mg, 15 mg, & 30 mg Rx only
Matching Channels
OxyContin, an narcotic analgesic produced by Purdue Pharma LP, nets $3m in sales annually, placing it 8th in the world for annual sales. OxyContin in the brand name for oxycodone, and is similar t...
Erectile dysfunction (ED or impotence) is the inability to get and maintain an erection that is sufficient for satisfactory sexual intercourse, and affects half of all men between the ages of 40 to...
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles'...
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secre...
Selective monoamine oxidase type B MAOB inhibitors
The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...
Matching News
Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02
An Investigational Agent Comprised Of Oxycodone Hydrochloride And Naltrexone Hydrochloride Extended-Release Capsules, In Subjects With Moderate-To-Severe Chronic Non-cancer Pain
Pfizer says top-line Ph III results show safety of pain drug ALO-02 as expected
safety study of its investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain support t...
Pfizer reports positive top-line results from Phase 3 pain study of ALO-02
Pfizer has reported positive top-line results from a Phase 3 open-label long-term safety study of ALO-02, oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules, in patients wi...
Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain
Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release cap...
Pfizer reports long-term safety of tamper-proof extended-release analgesic
Pfizer has announced that top-line data from an open-label Phase III study has provided evidence of the long-term safety of its investigational analgesic, ALO-02 (oxycodone hydrochloride and naltrexo...
FDA Oxycodone Enforcement Built On Difference Between “Same” And “Identical”
Companies must stop manufacturing unapproved single-ingredient, immediate-release oxycodone products in oral dosage forms within 45 days; FDA rejects Lannett petition, saying it has not provided evide...
Study finds reformulated ER Oxycodone abuse rates are significantly lower than original ER Oxycodone
(Inflexxion, Inc.) Aims of this study were to assess 1) whether the rates of abuse of extended-release (ER) oxycodone (OxyContin) decline following introduction of reformulated ER oxycodone (ORF), and...
AAPS PharmSciTech: Stability Enhancement of Drug Layered Pellets in a Fixed Dose Combination Tablet
Type: Original PaperThe purpose of this research was to develop a stable fixed dose combination tablet for a model DPP-IV inhibitor and metformin hydrochloride. The dipeptidyl peptidase IV (DPP-IV) in...
Matching PubMed Articles
PURPOSE: To characterize the pharmacokinetics (PK) of oxycodone following intravenous injection and administration of three oral dosage forms (solution, capsule, and controlled-release tablet) in elde...
Evaluation of performance of co crystals of mefloquine hydrochloride in tablet dosage form.
Objective: The objective of present investigation was to evaluate performance of cocrystals of Mefloquine Hydrochloride (MFL) in tablet dosage form. Our previous investigation showed significant effec...
Anomalous observations of hydrocodone in patients on oxycodone.
BACKGROUND: Urine drug monitoring is used by physicians treating chronic pain patients with opioid therapy. Patients are tested in part to insure that they are not taking other drugs. Therefore, the f...
The objective of this study was to achieve an optimal formulation of spray dried matrix type controlled-release (MTCR) microparticles containing tamsulosin hydrochloride for orally disintegrating tabl...
To study the release profiles of Ambroxol hydrochloride in matrix tablets with different fillers and controlled release materials, and investigate the potential impact on different fillers on the matr...
